Summary Box: Weak results end J&J antibiotic study

AP News
|
Posted: Jan 06, 2012 4:55 PM
Summary Box: Weak results end J&J antibiotic study

STUDY HALTED: A study aimed at winning approval of an additional use for Johnson & Johnson's intravenous antibiotic Doribax was halted because pneumonia patients fared better on an older combination drug.

RESULTS ANALYSIS: The Food and Drug Administration says significantly more study participants getting Doribax died and fewer were cured than in the comparison group.

DRUG'S FUTURE: Doribax is approved for abdominal and urinary tract infections. It's been under review by the FDA for use in pneumonia patients since 2007, when it was approved for the other uses.